Molecular Biology and Prevention of Endometrial Cancer
Annual rept. 17 Jun 2005-16 Jun 2006
HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE ROCKVILLE MD
Pagination or Media Count:
To increase our understanding of the molecular aberrations associated with endometrial carcinogenesis and the biologic mechanisms underlying the protective effect of oral contraceptive OC therapy. 1 Oligonucleotide microarray analysis was performed on a panel of endometrial cancers. 2 A subset of adenocarcinoma cases from the International DES Registry IDESR was analyzed for MSI 3 A case-control study of the CASH database was performed to evaluate the relationship between progestin potency and endometrial cancer risk. 4 An analysis of endometrium samples from cymologous macaques that were exposed to long term progestins was performed. 5 A clinical trial comparing progestin versus placebo is underway that will facilitate investigation of the effects of progestin exposure on the endometrial lining. 1 Different histological types of endometrial cancer have unique genomic expression patterns. 2 The poor quality DNA from the majority of IDESR samples prohibited an adequate analysis of the case set. 3 A case-control study has suggested higher progestin- potency OCs may be more protective than lower progestin potency OCs among women with a larger body habitus. 4 Macaque studies have suggested that induction of apoptosis may be a mechanism underlying the chemoprotective effects of progestin on the endometrium. 5 Regulatory hurdles have resulted in delays in initiation of the clinical trial. Final FDA approval is expected within the next 3-4 months and the original objectives in the statement of work will be addressed.
- Medicine and Medical Research